GLP-1 Agonists Effectively Reduce BMI in Patients with Inflammatory Bowel Disease
Semaglutide and tirzepatide significantly reduced BMI in non-diabetic IBD patients (median 8.15 kg loss) with manageable side effects and no apparent worsening of inflammatory markers.
Quick Facts
What This Study Found
BMI decreased significantly from 34.0 to 31.0 (p<0.0001) with median weight loss of 8.15 kg (p<0.0001). CRP and ALT levels did not change significantly, suggesting no worsening of IBD inflammation. Total cholesterol and HbA1c showed trends toward improvement. Side effects: nausea (31%), constipation (25%).
Key Numbers
Patients received semaglutide or liraglutide. The study tracked weight loss and metabolic parameters alongside IBD activity measures.
How They Did This
Single-center observational cohort study of 36 adult IBD patients (non-diabetic) started on semaglutide or tirzepatide for weight loss between January 2021 and April 2024. Primary outcomes: BMI and total body weight changes. Secondary outcomes: tolerability, safety, metabolic risk factors.
Why This Research Matters
IBD patients with obesity face unique challenges — their gut inflammation may interact with weight loss drugs in unpredictable ways, and concerns about GI side effects are amplified. This study provides the first evidence that GLP-1 agonists are both effective and apparently safe in IBD, filling an important clinical evidence gap.
The Bigger Picture
The intersection of obesity and IBD is a growing clinical challenge. Obesity worsens IBD outcomes, yet many weight loss interventions are concerning for patients with compromised gut function. These early data suggesting GLP-1 agonists work without worsening IBD are encouraging and may influence treatment guidelines for this growing patient population.
What This Study Doesn't Tell Us
Very small sample (36 patients) from a single center. Observational design without a control group. Short follow-up period. Did not specifically assess IBD disease activity scores (only CRP). The study couldn't differentiate between semaglutide and tirzepatide effects. 86% of patients were already on advanced IBD therapy, which may have masked any inflammatory effects.
Questions This Raises
- ?Do GLP-1 agonists have anti-inflammatory effects in the gut that could independently benefit IBD patients?
- ?Are there IBD-specific risks with long-term GLP-1 agonist use, such as effects on intestinal absorption or microbiome?
Trust & Context
- Key Stat:
- 8.15 kg median weight loss Non-diabetic IBD patients lost a median of 8.15 kg on GLP-1 agonists with no worsening of inflammatory markers — the first evidence of safety and efficacy in this unique population
- Evidence Grade:
- Preliminary evidence from a small, single-center observational study without a control group. Important as first-of-kind data in IBD patients, but requires validation in larger controlled trials.
- Study Age:
- Published in 2024, providing timely evidence as GLP-1 agonist prescribing rapidly expands and clinicians encounter more IBD patients requesting these medications.
- Original Title:
- Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.
- Published In:
- Digestive diseases and sciences, 69(12), 4437-4445 (2024)
- Authors:
- St-Pierre, Joëlle(2), Klein, Jeremy, Choi, Natalie K, Fear, Evan, Pannain, Silvana, Rubin, David T
- Database ID:
- RPEP-09316
Evidence Hierarchy
Frequently Asked Questions
Is it safe to take semaglutide if I have Crohn's disease or ulcerative colitis?
This small study suggests it can be — BMI decreased significantly without worsening inflammatory markers in 36 IBD patients. However, GI side effects like nausea and constipation may be more concerning for IBD patients. Discuss with your gastroenterologist, who can monitor your IBD activity while you're on the medication.
Could GLP-1 drugs actually help IBD?
Some preclinical research suggests GLP-1 has anti-inflammatory effects in the gut, but this hasn't been confirmed in IBD patients. In this study, inflammatory markers didn't worsen, which is reassuring. Whether there's a direct therapeutic benefit for IBD beyond weight loss is an open question.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09316APA
St-Pierre, Joëlle; Klein, Jeremy; Choi, Natalie K; Fear, Evan; Pannain, Silvana; Rubin, David T. (2024). Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.. Digestive diseases and sciences, 69(12), 4437-4445. https://doi.org/10.1007/s10620-024-08720-2
MLA
St-Pierre, Joëlle, et al. "Efficacy and Safety of GLP-1 Agonists on Metabolic Parameters in Non-diabetic Patients with Inflammatory Bowel Disease.." Digestive diseases and sciences, 2024. https://doi.org/10.1007/s10620-024-08720-2
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of GLP-1 Agonists on Metabolic Parameter..." RPEP-09316. Retrieved from https://rethinkpeptides.com/research/st-pierre-2024-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.